-
公开(公告)号：US11845715B2
公开(公告)日：2023-12-19
申请号：US17405989
申请日：2021-08-18
申请人： THE UNIVERSITY OF QUEENSLAND , THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
发明人： Luke O'Neill , Rebecca Coll , Matthew Cooper , Avril Robertson , Kate Schroder
IPC分类号： C07C311/56 , A61P17/00 , C07D403/12 , C07D249/12 , C07D249/04 , C07D241/42 , A61P25/00 , A61P37/00 , C07D495/04 , C07D241/44 , C07D277/36 , C07D307/68 , C07D487/04 , C07D215/36 , C07D249/06 , C07D311/16 , C07D401/06 , C07D401/12 , A61P3/00 , C07C311/60 , C07D213/71 , C07D217/22 , C07D221/18 , C07D317/62 , C07D333/34 , A61P1/00 , A61P35/00 , C07D217/02 , C07D241/24 , C07D271/12 , C07D413/12 , C07D417/12 , A61P5/00 , C07D307/18 , C07D307/64 , C07D311/60 , C07D333/52 , C07D333/62 , C07D405/12 , C07D495/06 , C07D217/24 , C07D235/02 , C07D311/18 , C07D407/12 , C07D231/18 , C07D307/82 , C07D309/08 , C07D493/04 , C07D207/38 , C07D261/18 , C07D498/04
CPC分类号： C07C311/56 , A61P1/00 , A61P3/00 , A61P5/00 , A61P17/00 , A61P25/00 , A61P35/00 , A61P37/00 , C07C311/60 , C07D207/38 , C07D213/71 , C07D215/36 , C07D217/02 , C07D217/22 , C07D217/24 , C07D221/18 , C07D231/18 , C07D235/02 , C07D241/24 , C07D241/42 , C07D241/44 , C07D249/04 , C07D249/06 , C07D249/12 , C07D261/18 , C07D271/12 , C07D277/36 , C07D307/18 , C07D307/64 , C07D307/68 , C07D307/82 , C07D309/08 , C07D311/16 , C07D311/18 , C07D311/60 , C07D317/62 , C07D333/34 , C07D333/52 , C07D333/62 , C07D401/06 , C07D401/12 , C07D403/12 , C07D405/12 , C07D407/12 , C07D413/12 , C07D417/12 , C07D487/04 , C07D493/04 , C07D495/04 , C07D495/06 , C07D498/04 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2602/08 , C07C2602/10 , C07C2603/10
摘要： The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.
-
公开(公告)号：US20220112159A1
公开(公告)日：2022-04-14
申请号：US17405989
申请日：2021-08-18
申请人： THE UNIVERSITY OF QUEENSLAND , THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOL
发明人： Luke O'NEILL , Rebecca Coll , Matthew Cooper , Avril Robertson , Kate Schroder
IPC分类号： C07C311/56 , A61P17/00 , C07D403/12 , C07D249/12 , C07D249/04 , C07D241/42 , A61P25/00 , A61P37/00 , C07D495/04 , C07D241/44 , C07D277/36 , C07D307/68 , C07D487/04 , C07D215/36 , C07D249/06 , C07D311/16 , C07D401/06 , C07D401/12 , A61P3/00 , C07C311/60 , C07D207/38 , C07D213/71 , C07D217/22 , C07D221/18 , C07D317/62 , C07D333/34 , A61P1/00 , A61P35/00 , C07D217/02 , C07D241/24 , C07D271/12 , C07D413/12 , C07D417/12 , A61P5/00 , C07D261/18 , C07D307/18 , C07D307/64 , C07D311/60 , C07D333/52 , C07D333/62 , C07D405/12 , C07D495/06 , C07D217/24 , C07D235/02 , C07D311/18 , C07D407/12 , C07D231/18 , C07D307/82 , C07D309/08 , C07D493/04 , C07D498/04
摘要： The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.
-
公开(公告)号：US10513503B2
公开(公告)日：2019-12-24
申请号：US15577173
申请日：2016-05-27
申请人： BIOPHYTIS , UNIVERSITE PIERRE ET MARIE CURIE—PARIS 6 (UPMC) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
IPC分类号： C07D311/60 , A61K31/352
摘要： Disclosed is a method for the treatment, prevention and/or stabilisation of ARMD, Stargardt disease, pigmentary retinopathy and/or diabetic retinopathy, including the application of a 3-deoxyanthocyanidin of formula (I) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and X− are as defined, with the condition that at least one of R1, R2, R3, R4 or R5 is a hydroxyl and at least one of R8, R9, R10 or R11 is a hydroxyl.
-
公开(公告)号：US20180230119A1
公开(公告)日：2018-08-16
申请号：US15577173
申请日：2016-05-27
申请人： BIOPHYTIS , UNIVERSITE PIERRE ET MARIE CURIE - PARIS 6 (UPMC) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
IPC分类号： C07D311/60
摘要： Disclosed is a method for the treatment, prevention and/or stabilisation of ARMD, Stargardt disease, pigmentary retinopathy and/or diabetic retinopathy, including the application of a 3-deoxyanthocyanidin of formula (I) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and X− are as defined, with the condition that at least one of R1, R2, R3, R4 or R5 is a hydroxyl and at least one of R8, R9, R10 or R11 is a hydroxyl.
-
公开(公告)号：US09840487B2
公开(公告)日：2017-12-12
申请号：US15487592
申请日：2017-04-14
发明人： Karl A. Scheidt , Bi-Shun Zeng
IPC分类号： C07D311/60
CPC分类号： C07D311/60 , C07B53/00 , C07D311/32 , C07D311/62 , C07F9/59 , C07F9/65515 , C07F9/657154
摘要： Methods to access 2-aryl chromene compounds via an asymmetric catalytic process.
-
公开(公告)号：US20170217919A1
公开(公告)日：2017-08-03
申请号：US15487592
申请日：2017-04-14
申请人： Karl A. Scheidt , Bi-Shun Zeng
发明人： Karl A. Scheidt , Bi-Shun Zeng
IPC分类号： C07D311/60
CPC分类号： C07D311/60 , C07B53/00 , C07D311/32 , C07D311/62 , C07F9/59 , C07F9/65515 , C07F9/657154
摘要： Methods to access 2-aryl chromene compounds via an asymmetric catalytic process.
-
公开(公告)号：US20170217918A1
公开(公告)日：2017-08-03
申请号：US15328735
申请日：2015-08-06
申请人： Helen CHEN , Steven L. COLLETTI , Duane MONG , Yan GUO , Michael MILLER , Anilkumar NAIR , Christopher W. PLUMMER , Dong XIAO , De-Yi YANG , Merck Sharp & Dohme Corp.
发明人： Helen Chen , Steven L. Colletti , Duane DeMong , Yan Guo , Michael Miller , Anilkumar Nair , Christopher W. Plummer , Dong Xiao , De-Yi Yang
IPC分类号： C07D311/60 , C07D405/14 , C07D471/08 , C07D487/08 , C07D487/04 , C07D491/107 , C07D413/12 , C07D491/08 , C07D405/10 , C07D491/048
CPC分类号： C07D311/60 , A61K31/366 , A61K31/397 , A61K31/4985 , A61K45/06 , C07D405/10 , C07D405/14 , C07D413/12 , C07D413/14 , C07D451/02 , C07D471/08 , C07D487/04 , C07D487/08 , C07D491/048 , C07D491/08 , C07D491/107 , A61K2300/00
摘要： Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号：US20170166548A1
公开(公告)日：2017-06-15
申请号：US15225271
申请日：2017-03-08
申请人： SANOFI
发明人： Werngard CZECHTIZKY , John WESTON , Nils RACKELMANN , Volker KRAFT , Petra ARNDT , Klaus WIRTH , Heinz GOEGELEIN , Olaf RITZELER
IPC分类号： C07D311/60 , C07D413/12 , C07D417/12 , C07D407/12 , C07D405/12 , C07D409/12
CPC分类号： C07D311/60 , C07D405/12 , C07D407/12 , C07D407/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14 , C07F9/65522
摘要： The present invention relates to substituted chroman-6-yloxy-cycloalkanes of the formula (I) in which Ar, R1 to R4, p and q are as defined in the claims. The compounds of the formula (I) are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use in pharmaceuticals, and pharmaceutical compositions comprising them.
-
公开(公告)号：US09656984B2
公开(公告)日：2017-05-23
申请号：US15025086
申请日：2014-09-24
申请人： UNIVERSITE DE RENNES 1 , Centre national de la recherche scientifique , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
IPC分类号： C07D311/60 , C07D335/06 , C07D407/04 , C07D495/04 , C07D493/10 , C07D409/04 , C07D311/64
CPC分类号： C07D311/60 , C07D311/64 , C07D335/06 , C07D407/04 , C07D409/04 , C07D493/10 , C07D495/04
摘要： The invention relates to new PI3K/AKT/m TOR inhibitors and their use for the prevention and/or the treatment of a disease selected from the group consisting of: inflammatory diseases, autoimmune diseases, neurodegenerative diseases, cancers, transplant rejection, diseases characterized by a premature aging and tuberous sclerosis.
-
10.发明授权Inorganic nanoparticle deposited catalyst for hydrogenation and manufacturing method of the same, and hydrogenation for biomass derived hydrocarbon compounds 有权无机纳米颗粒沉积催化剂用于氢化及其制备方法相同，并对生物质衍生烃化合物进行氢化公开(公告)号：US09421527B2
公开(公告)日：2016-08-23
申请号：US14513529
申请日：2014-10-14
发明人： Dong-Pyo Kim , Ajay K. Singh
IPC分类号： B01J27/24 , C07C41/18 , C07C29/17 , C07C45/62 , C07C51/36 , C07D311/60 , C07C5/03 , C07C209/36 , C07C221/00 , B01J23/44 , B01J23/745 , B01J23/89 , B01J23/75 , C07C37/00 , C07C41/01 , C07C231/10 , B01J37/03 , B01J37/16 , B01J37/34 , B01J21/18 , B01J23/42 , B01J23/50 , B01J23/52 , B01J35/00 , C07C1/22 , C07C5/08
CPC分类号： B01J27/24 , B01J21/18 , B01J23/42 , B01J23/44 , B01J23/50 , B01J23/52 , B01J23/745 , B01J23/75 , B01J23/8906 , B01J23/8913 , B01J35/0013 , B01J35/002 , B01J35/0033 , B01J35/1019 , B01J37/031 , B01J37/16 , B01J37/343 , C07C1/22 , C07C5/03 , C07C5/08 , C07C29/172 , C07C37/002 , C07C41/01 , C07C41/18 , C07C45/62 , C07C51/36 , C07C209/36 , C07C221/00 , C07C231/10 , C07C2521/18 , C07C2523/89 , C07C2601/14 , C07C2603/18 , C07D311/60 , C10G3/45 , C10G3/50 , C10G3/55 , C10G2300/1011 , C10G2300/70 , C10G2400/02 , C10G2400/04 , C10G2400/06 , C10G2400/08 , Y02P20/52 , Y02P30/20 , C07C43/23 , C07C43/205 , C07C39/07 , C07C43/164 , C07C31/125 , C07C211/46 , C07C233/03 , C07C57/30 , C07C47/228 , C07C49/403 , C07C13/18 , C07C9/15 , C07C15/073
摘要： A hydrogenation catalyst and a method of hydrogenating a hydrocarbon compound as a substrate using the same are provided. The hydrogenation catalyst includes inorganic nanoparticles and a nitrogen-doped reduced graphene oxide support for supporting the inorganic nanoparticles, and the hydrocarbon compound is derived from a biomass and contains a functional group. Therefore, the hydrogenation catalyst which exhibits a high conversion rate and high selectivity, is stable, and can be easily separated after a hydrogenation reaction, and whose catalytic activities are not significantly altered even when recovered and repeatedly recycled can be provided. The method of hydrogenating a hydrocarbon compound in which hydrogen can be directly produced in a reactor using formic acid as a hydrogen source without supplying additional hydrogen gas and simultaneously be used under normal pressure can also be provided.
摘要翻译： 提供氢化催化剂和使用其的氢化烃化合物作为底物的方法。 氢化催化剂包括无机纳米颗粒和用于支撑无机纳米颗粒的氮掺杂的还原型石墨烯氧化物载体，烃化合物衍生自生物质并含有官能团。 因此，显示高转化率和高选择性的氢化催化剂是稳定的，并且可以容易地在氢化反应之后分离，并且即使在回收和反复再循环时催化活性也不会显着改变。 也可以提供氢化氢化合物的方法，其中可以使用甲酸作为氢源在反应器中直接生产氢气，而不提供额外的氢气并同时在常压下使用。
-
-
-
-
-
-
-
-
-
搜索结果
185 条记录 (耗时 0.042 秒)
